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Abstract
Background. Increased oxidative stress is a hallmark of
end-stage renal disease (ESRD). Glutathione S-transferases
(GST) are involved in the detoxiﬁcation of xenobiotics
and protection of oxidative damage. We hypothesized that
genetic polymorphism in antioxidant enzymes GSTA1,
GSTM1, GSTP1 and GSTT1 is more frequent in ESRD and
modulates the degree of oxidative stress in these patients.
Methods. GSTA1, GSTM1, GSTP1 and GSTT1 genotypes
were determined in 199 ESRD patients and 199 age- and
gender-matched controls. Markers of protein and lipid oxi-
dative damage [thiol groups, carbonyl groups, advanced
oxidative protein products, nitrotyrosine, malondialdehyde
(MDA) and MDA adducts], together with total oxidant
status and pro-oxidant–antioxidant balance were deter-
mined.
Results. Individual GST polymorphisms inﬂuence vulner-
ability to both protein and lipid oxidation, with GSTM1-null
gene variant having the most pronounced effect. Further-
more, a strong combined effect of null/low-activity GSTM1,
GSTT1, GSTA1 and GSTP1 genotypes in terms of suscepti-
bility towards oxidative and carbonyl stress was found in
ESRD patients. When patients were stratiﬁed according to
GSTM1 and GSTT1, the highest oxidant damage was noted
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in those with the GSTM1-null/GSTT1-null genotype. The
observed effect was even stronger in patients with the third
low-activity GSTP1 or GSTA1 genotype. Finally, the level
of oxidative and carbonyl stress was most pronounced in the
subgroup of patients with all four null or low-activity
GSTM1, GSTT1, GSTP1 and GSTA1 genotypes.
Conclusions. According to the GST genotype, ESRD
patients may be stratiﬁed in terms of the level of oxidative
and carbonyl stress that might inﬂuence cardiovascular
prognosis, but could also improve efforts towards individua-
lization of antioxidant treatment.
Keywords: end-stage renal disease; glutathione S-transferases;
haemodialysis; oxidative stress; polymorphism
Introduction
There is a mounting evidence for the presence of oxi-
dative stress in patients undergoing maintenance haemo-
dialysis (MHD) [1–6], contributing to poor cardiovascular
(CV) and overall outcome [7]. Both increased free rad-
icals production and down-regulated antioxidant enzymes
activities contribute to protein, lipid and DNA oxidative
damage by-products accumulation in dialysis patients
[8–11]. In addition to the well-established link of
oxidative stress with speciﬁc causes of renal failure, dialy-
sis procedure and uraemic state, the role of genetic predis-
position in enhanced oxidative damage and consequent
worsening of MHD patients’ prognosis has emerged
recently.
Members of the glutathione transferase (GST) enzyme
superfamily are able to detoxify accumulated uraemic
toxins in MHD patients and posses strong antioxidant
activity towards reactive oxygen species (ROS) and per-
oxides [12 –14]. However, as recently shown by Lin et al.
[10], the capacity to evoke the GST response towards oxi-
dative stress in MHD patients seems to be genetically de-
termined. Namely, almost all members of GST family
exhibit genetic polymorphism, resulting in complete lack
or lowering of enzyme activity [15]. Approximately half
of the population lacks GSTM1 enzyme activity, due to a
homozygous deletion of the GSTM1 gene [16]. The
GSTM1-null genotype has attracted much attention as a
result of risk linkage with lung and bladder cancer [17,
18] and increased susceptibility to coronary heart disease
among smokers [19, 20]. Haemodialysis (HD) patients
lacking GSTM1 activity exhibit enhanced oxidative DNA
damage and higher mortality rate than those with active
GSTM1 enzyme [10]. Despite the fact that protein and
lipid oxidative modiﬁcations have a key role in the patho-
genesis of CV complications in these patients, the ques-
tion of whether the GSTM1 genotype inﬂuences the level
of protein and lipid oxidative damage by-products in
MHD patients has not been well established as yet.
In addition to the GSTM1 polymorphism, GSTT1,
GSTP1 and GSTA1 polymorphisms also gained a lot of
attention. In the case of GSTT1, gene homozygous del-
etion present in ∼20% of Caucasians, leads to the lack of
GSTT1 enzyme activity [21]. Single-nucleotide
polymorphism (SNP) leading to amino acid substitution
from isoleucine (Ile) to valine (Val) [22] changes catalytic
activity of the GSTP1 enzyme [23]. Thus, if Val is present
in GSTP1, speciﬁc substrates might accumulate and
contribute to oxidative damage [23–25]. In healthy Cau-
casians, the frequencies of the genotype variants of
GSTP-Ile/Ile, -Ile/Val and -Val/Val are 51.5, 39.4, and
9.1%, respectively [26]. GSTA1 polymorphism is rep-
resented by three, apparently linked, SNPs: -567TOG,
-69COT and -52GOA. These substitutions result in differ-
ential expression with lower transcriptional activation of
the variant GSTA1*B (-567G, -69T, -52A) than common
GSTA1*A allele (-567T, -69C,-52G) [27]. It seems reason-
able to assume that GSTT1-null or GSTA1- or GSTP1-
low-activity genotypes might also inﬂuence the level of
oxidative stress in MHD patients and thus contribute to
endogenous predisposition to oxidative damage in the
setting of disrupted redox balance. Still, the role of poly-
morphic expression of GSTA1, GSTP1 and GSTT1 genes
in increased oxidant-induced protein and lipid damage
among MHD patients has to be established. This has
prompted us to assess whether the null or low-activity
GSTM1, GSTT1, GSTP1 and GSTA1 genotype alone or in
combination correlate with eight biomarkers of oxidative
stress, including protein thiol and carbonyl groups, ad-
vanced oxidation protein products (AOPP), nitrotyrosine,
malondialdehyde (MDA), MDA adducts, total oxidant




A total of 199 patients (84 male and 115 female, mean age 60.0 ± 12.1
years) undergoing HD treatment for 12–15 h weekly in two dialysis
facilities in Belgrade (Center for Renal Diseases, Zvezdara University
Medical Center and Department of Nephrology and Hemodialysis, Uni-
versity Teaching Hospital Zemun) were included in this case–control
study. All patients were stable, aged over 21 and with HD vintage >3
months before the study. Exclusion criteria were malignancy or infec-
tious co-morbidity based on C-reactive protein values. Patients did not
receive any antioxidant therapy (vitamin C or E), while 35.2% of
patients received angiotensin-converting inhibitors therapy and 15.1% re-
ceived statins.
The causes of end-stage renal disease (ESRD) were hypertensive ne-
phrosclerosis (n = 93), glomerulonephritis (n = 32), diabetic nephropathy
(n = 25), polycystic renal disease (n = 19), pyelonephritis (n = 19),
Balkan endemic nephropathy (n = 7) and obstructive nephropathy
(n = 4). Patients were treated with single-use dialysers equipped with
low- and high-ﬂux polysulphone membranes, with a membrane surface
area of 1.3–2.1. m². A total of 199 controls (85 male and 114 female,
mean age 59.3 ± 10.9 years) were recruited from individuals with ne-
phrolithiasis and normal renal function who were admitted to the same
hospitals during the same time period. All the participants provided
written informed consent. This study protocol was approved by the Insti-
tutional Review Board, and the research was carried out in compliance
with the Helsinki Declaration (as revised in 2000).
GST genotyping
Genomic DNA was isolated from whole blood using the QIAGEN
QIAmp kit (Qiagen, Inc., Chatsworth, CA).
GSTA1 C-69T polymorphism was determined by polymerase chain
reaction–restriction fragment length polymorphism (PCR–RFLP)
by Ping et al. [28]. The primers used were GSTA1 C-69T forward:
5′-TGTTGATTGTTTGCCTGAAATT-3′ and GSTA1 C-69T reverse:
5′-GTTAAACGCTGTCACCCGTCCT-3′. The presence of restriction site
resulting in two fragments (385 and 96 bp) indicated mutant allele (T/T)
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and if C/T polymorphism incurred, it resulted in one more fragment of
481 bp (Figure 1A).
GSTM1 genotyping was performed by multiplex PCR [29]. Primers
used were GSTM1 forward: 5′-GAACTCCCTGAAAAGCTAAAGC-3′
and GSTM1 reverse: 5′-GTTGGGCTCAAATATACGGTGG-3′. Exon 7
of the CYP1A1 gene was co-ampliﬁed and used as an internal control
using the following primers: CYP1A1 forward: 5′-GAACTGCCACTT
CAGCTGTCT-3′ and CYP1A1 reverse: 5′-CAGCTGCATTTG
GAAGTGCTC-3′. The presence of the GSTM1-active genotype was de-
tected by the band at 215 bp, since the assay does not distinguish hetero-
zygous or homozygous wild-type genotypes (Figure 1B).
GSTP1 Ile105Val polymorphism was analysed using the PCR–RFLP
method by Harries et al. [30]. Primers used were: GSTP1 Ile105Val
forward: 5′-ACCCCAGGGCTCTATGGGAA-3′ and GSTP1 Ile105Val
reverse: 5′-TGAGGGCACAAGAAGCCCCT-3′. The presence of restric-
tion site resulting in two fragments (91 and 85 bp) indicated mutant
allele (Val/Val), while if Ile/Val polymorphism incurred, it resulted in one
more fragment of 176 bp (Figure 1C).
GSTT1 genotyping was performed by multiplex PCR [29]. Primers
used were GSTT1-forward: 5′-TTCCTTACTGGTCCTCACATCTC-3′
and GSTT1-reverse: 5′-TCACGGGATCATGGCCAGCA-3′. The assay
does not distinguish between heterozygous or homozygous wild-type
genotypes; therefore, the presence of 480 bp bands was indicative for the
GSTT1-active genotype (Figure 1D).
Biomarkers of oxidative damage in plasma
Spectrohotometrical analysis was performed for protein thiol groups
(method of Jocelyn) [31], AOPP (modiﬁed method of Witko-Sarsat
et al.) [5], MDA (method of Dousset et al.) [32], TOS (method of Erel)
[33] and PAB (method of Alamdari et al.) [34].
Carbonyl protein derivatives content, MDA protein adducts and nitro-
tyrosine were measured by enzyme immunoassay (OxiSelectTM ELISA
kits, Cell Biolabs).
Statistical analysis
In descriptive statistics, we summarized all continuous variables by
means ± standard deviations (SD). Differences in investigated parameters
were assessed by using analysis of variance (ANOVA) for continuous
variables and χ2 for categorical variables. The associations between the
genotypes and ESRD risk were calculated by using logistic regression to
compute odds ratios (ORs) and corresponding 95% conﬁdence intervals
(CIs), adjusted according to age and gender as potential confounding
factors.
In the ﬁrst step of statistical evaluation of relationships between bio-
markers of oxidative damage (SH groups, carbonyls, AOPP, nitrotyro-
sine, MDA, MDA adducts, TOS, PAB) and combined GSTA1, GSTM1,
GSTP1 and GSTT1 genotypes in ESRD patients, distribution was tested
by using the Kolmogorov–Smirnov test. For normally distributed
data, we performed ANOVA and, if necessary, the Bonferroni post hoc
test for locating differences between multiple groups. For data with a
non-normal distribution, we used the Mann–Whitney rank-sum test
(for between-two-group comparisons) and the Kruskal–Wallis non-para-
metric test that compared three unpaired groups.
Two-tailed P-values of <0.05 were considered signiﬁcant. Data were
analysed using the Statistical Package for the Social Sciences (SPSS)
(version 17.0, Chicago, IL).
Results
Baseline patients’ characteristics are presented in Table 1.
No signiﬁcant difference was observed, except for bio-
chemical parameters of renal function.
GST genotypes and ESRD risk
The distribution of GST genotypes in ESRD patients and
controls is presented in Table 2. The frequency of GSTA1,
Fig. 1. Agarose gel electrophoretogram. PCR–RFLP products of the
GSTA1 gene. Lanes 4 and 9 represent the GSTA1 CC genotype. Lanes 1,
2, 5, 6 and 10 represent the GSTA1 CT genotype, while lanes 3, 7 and 8
represent the GSTA1 TT genotype (A). PCR products of the GSTM1
gene are showed in (B). Lanes 1, 2, 9, 11 and 12 are patients with the
GSTM1 active genotype and lanes 3 through 8 with lane 10 represent the
GSTM1 null genotype (B). PCR–RFLP products of the GSTP1 gene.
Lanes 1 and 2 are wild-type (Ile/Ile), lanes 3, 4 and 5 are heterozygotes
(Ile/Val) and lane 6 is homozygote (Val/Val) (C). PCR products of the
GSTT1 gene. Lanes 1, 3, 4 and 5 are patients with the GSTT1 active
genotype and lane 2 represents the GSTT1 null genotype (D). M, DNA
marker; N, negative control.




Male (%) 84 (42) 85 (43)
Female (%) 115 (58) 114 (57)
Age (year)a 60.0 ± 12.1 59.3 ± 10.9
Time on haemodialysis (year)a 6.3 ± 4.4 —
Biochemical serum parametersa
Albumin (g/L) 39.6 ± 4.0 43.5 ± 2.6*
Urea (mmol/L) 24.4 ± 4.8 5.5 ± 1.2*
Creatinine (μmol/L) 880.2 ± 238.6 84.4 ± 10.3*
Triacylglycerol (mmol/L) 2.1 ± 1.3 1.4 ± 0.4*
Haemoglobin (g/L) 108.1 ± 15.4 144.0 ± 13.7*
Serum iron (μmol/L) 11.3 ± 5.6 21.1 ± 4.8*
Ferritin (ng/mL) 350.2 ± 278.0 48.0 ± 29.6*
Haematocrit (%) 32.1 ± 5.2 39.8 ± 4.9*
aAll results are presented as mean ± SD.
*P < 0.001.
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GSTM1, GSTP1 and GSTT1 null/low-activity genotypes
was higher in ESRD patients than in controls. Signiﬁ-
cant association between the GST genotype and risk of
ESRD development was found only for the GSTM1 gen-
otype. Individuals with GSTM1-null were at 1.6-fold
higher risk of ESRD development (OR = 1.6, 95%
CI = 1.1–2.4, P = 0.024) than individuals carrying the
GSTM1-active genotype. When GST genotypes were
analysed in combination (Table 3), the highest risk of
ESRD development was obtained in subjects who
carried both GSTM1 and GSTT1-null genotypes
(OR = 2.0, 95% CI = 1.1–3.7, P = 0.025). Combination
of GSTM1-null with the GSTP1-low-activity genotype
was also found to be signiﬁcant (OR = 1.8, 95%
CI = 1.0–3.1, P = 0.042). The GSTM1-null/GSTA1-low-
activity combination had certain effect on ESRD risk
(OR = 1.8; 95% CI = 0.9–3.3, P = 0.058).
Association between GST genotype and biomarkers of
oxidative damage
The degree of oxidative and nitrosative protein damage in
ESRD patients stratiﬁed according to GST genotypes is
presented in Figure 2. Plasma protein thiol groups concen-
tration was signiﬁcantly lower in patients with both
GSTM1 or GSTT1-null, as well as, GSTP1-low-activity
genotype in comparison to corresponding active genotype
(P = 0.001, 0.002 and 0.042, respectively) (Figure 2A).
Signiﬁcantly higher plasma carbonyl groups levels were
found in patients with low-activity GSTA1-TT or GSTM1-
null genotype (P = 0.007 and 0.005, respectively)
(Figure 2B). AOPP concentrations were increased in
patients carrying the GSTM1- or GSTT1-null genotype
(P = 0.001 and 0.037, respectively) (Figure 2C). As
presented, the most pronounced effect regarding protein
oxidative damage was observed for the GSTM1 genotype
(Figure 2). Furthermore, nitrotyrosine, a reliable marker of
nitrosative damage of proteins, was found to be higher in
patients with the GSTP1-low-activity genotype (P = 0.07)
(Figure 2D).
MDA, a commonly used biomarker of lipid oxidative
damage, exists both as free and bound to proteins, nucleic
acids and lipoproteins which are designated as MDA
adducts. Both free and MDA adduct levels were signiﬁ-
cantly increased in patients with GST null/low-activity
genotypes (Figure 3).
Since the effects of different oxidant molecules are
additive, we determined the TOS and PAB. Similar to
previous results, patients with GST null or low-activity
genotypes had increased plasma TOS and PAB levels,
with the GSTM1-null genotype carriers having the
highest levels (P = 0.001) (Figure 4A). Increased TOS
and PAB concentrations were also found in patients
with GSTT1-null genotype, but did not reach statistical
signiﬁcance.
To assess whether the effects of null/low-activity GST
genotypes are more pronounced when combined, we com-
pared the level of oxidative damage between ESRD
patients stratiﬁed according to the various combinations
of GST gene variants (Table 4). The level of oxidative
damage of proteins and lipids was lowest in patients with
both GSTSM1- and GSTT1-active genotypes, then gradu-
ally increased in GSTM1-active/GSTT1-null and GSTM1-
null/GSTT1-active ESRD patients, reaching the highest
values in patients with both GSTM1- and GSTT1-null
genotypes (Table 4). The observed effect was even more
obvious if patients were stratiﬁed according to the combi-
nation of three GST genotypes (Table 4). Furthermore,
when a combination of all four GST genotypes tested was
analysed, we found striking evidence in favour of in-
creased susceptibility to lipid peroxidation and protein
oxidative and nitrosative damage in ESRD patients carry-
ing combined GSTM1/GSTT-null and low-activity GSTA1
and GSTP1 genotypes (Table 4). On the other hand, car-
riers of combined active GSTM1, GSTT1, GSTP1 and
GSTT1 genotypes had the lowest level of oxidative stress
among ESRD patients.
Discussion
High levels of free radicals that occur in the course of
chronic renal failure (CRF) are associated with the disease
pathogenesis, its progression and complications [11, 35].
Based on this premise, we speculated that variations in
detoxifying and antioxidant activities of GST modulate
individual tendency towards ESRD development, regard-
less of its speciﬁc cause. Among four common GST poly-
morphisms analysed in this study, only the GSTM1-null
genotype has shown a signiﬁcant association with ESRD
that was more pronounced if any of the other three null/
low-activity GST genotypes was also present. Our results
on the association between GSTM1-null genotype and in-
creased risk of ESRD development are in accordance with
several studies performed in Indian population [36–38].
Table 2. GSTA1, GSTM1, GSTP1 and GSTT1 genotypes in relation to









CC 70 (35.2) 78 (39.2) 1.0a
CT 90 (45.2) 94 (47.2) 1.1 (0.7–1.7) 0.110
TT 39 (19.6) 27 (13.6) 1.6 (0.9–2.9) 0.746
CT + TT 129 (64.8) 121 (60.8) 1.2 (0.8–1.8) 0.401
GSTM1
*1 activeb 80 (40.2) 102 (51.3) 1.0a
*0 nullc 119 (59.8) 97 (48.7) 1.6 (1.1–2.4) 0.024
GSTP1
Ile/Ile 75 (37.7) 82 (41.2) 1.0a
Ile/Val 77 (38.7) 84 (42.2) 1.0 (0.6–1.5) 0.939
Val/Val 47 (23.6) 33 (16.6) 1.6 (0.9–2.7) 0.112
Ile/
Val + Val/Val
124 (62.3) 117 (58.8) 1.1 (0.8–1.7) 0.531
GSTT1
*1 activeb 132 (66.3) 142 (71.4) 1.0a
*0 nullc 67 (33.7) 57 (28.6) 1.2 (0.8–1.9) 0.319
OR, odds ratio; CI, conﬁdence interval; Ca, number of patients; Co,
controls.
aReference category.
bActive (present) if at least one active allele present.
cInactive (null) if no active alleles present.
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However, such association was not found among Taiwan
Chinese [39], population of Taipei [10] and Asian Indians
ESRD patients [40]. With regard to the GSTT1-null
genotype, two studies revealed that the GSTT1-null geno-
type inﬂuences higher risk for ESRD development [37,
39]. The role of low-activity GSTP1-Val/Val
Table 3. Combined effects of GSTA1, GSTM1, GSTP1 and GSTT1 genotypes in relation to the risk of ESRD
GSTM1 GSTA1 GSTP1
Presenta Nullb Activea Low activityc Activea Low activityc
GSTA1
Activea
Ca/Co 29/36 41/42 — — — —
OR (95% CI) 1.0d 1.2 (0.6–2.3)
Low activityc
Ca/Co 48/64 78/55 — — — —
OR (95% CI) 0.9 (0.5–1.8) 1.8 (0.9–3.3)
GSTP1
Activea
Ca/Co 34/50 41/32 30/33 45/49 — —
OR (95% CI) 1.0d 2.1 (1.1–4.0)e 1.0d 1.0 (0.5–2.0)
Low activityc
Ca/Co 45/52 78/65 40/45 84/72 – –
OR (95% CI) 1.3 (0.7–2.4) 1.8 (1.0–3.1)e 1.0 (0.5–1.9) 1.2 (0.7–2.3)
GSTT1
Presenta
Ca/Co 51/73 81/69 48/56 85/85 55/62 77/80
OR (95% CI) 1.0d 1.7 (1.1–2.8)e 1.0d 1.2 (0.7–1.9) 1.0d 1.1 (0.7–1.7)
Nullb
Ca/Co 28/30 38/27 22/22 45/35 20/20 47/37
OR (95% CI) 1.3 (0.7–2.5) 2.0 (1.1–3.7)e 1.1 (0.5–2.3) 1.5 (0.8–2.7) 1.2 (0.6–2.5) 1.4 (0.8–2.5)
OR, odds ratio; CI, conﬁdence interval.
aActive (present) if at least one active allele present.
bNull if no active alleles present.
cLow activity if at least one lower activity allele present.
dReference group.
eStatistically signiﬁcant difference when compared with the reference group.
Fig. 2. Protein oxidative damage biomarkers in relation to the GST genotype in ESRD patients. Plasma thiol groups decreased in patients with null/
low-activity GST genotype (A). Carbonyl groups, AOPP and nitrotyrosine content in plasma increased in patients with null/low-activity GST
genotype (B–D, respectively). *P < 0.05, **P < 0.01.
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polymorphism was addressed in only two studies [36,
40], in which it was also associated with increased ESRD
risk. Taken together, these data suggest the existence of
ethnic-speciﬁc GST genetic susceptibility to ESRD devel-
opment. To our knowledge, this is the ﬁrst investigation
that addressed the susceptibility to ESRD in European
Caucasians in association to common GST polymorph-
isms. Our data on combined effect of various GST geno-
types on ESRD development are in accordance with
previous investigations of GSTM1/GSTT1 [37] and
GSTM1/T1/P1 [36] genotype combinations in Northern
Indian patients, although the magnitude of this association
was lower in our population. Differential susceptibility to
ESRD in various populations might not only be the con-
sequence of differences in the genetic distribution of
GSTs among ethnic groups, but also due to the different
aetiology of ESRD in various regions. Since ESRD
among our patients had distinct aetiology and could
hardly be associated with environmental agents metab-
olized by GST enzymes, except for Balkan endemic ne-
phropathy, weak association obtained for GSTM1-null and
its absence with other GST forms is not unexpected. It is
reasonable to assume that GST polymorphic expression
may be much more important in the course of CRF pro-
gression, since accumulated end-products of endogenous
and exogenous origin and ROS in these patients act as
GST substrates [41]. This is a situation in which gene
interaction with disease-speciﬁc mechanisms inﬂuences
further course of disease.
The assumption that lack or low-activity GST gene var-
iants contribute to increased susceptibility to oxidative
and carbonyl stress in ESRD has been conﬁrmed in the
next phase of this investigation, in which the inﬂuence of
polymorphic GSTA1, GSTM1, GSTP1 and GSTT1 genes
was analysed with respect to oxidative phenotype. Oxi-
dative stress in ESRD has multifactorial origin, including
low molecular weight uraemic toxins, elevated homocys-
teine level, increased carbonyl stress, with decreased
expression of extracellular glutathione peroxidase pro-
duced by renal parenchymal cells, as well as, exacer-
bations of oxidative stress by dialysis sessions and severe
chronic inﬂammation [11, 35, 42]. Oxidative stress in
ESRD patients is considered the cornerstone of athero-
sclerotic process. Carotid artery intima-media thickness in
Fig. 3. Lipid oxidative damage biomarkers in relation to the GST genotype in ESRD patients. Plasma MDA concentrations and MDA adducts
content increased in patients with null/low-activity GST genotype (A and B, respectively). *P < 0.05, **P < 0.01.
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chronic HD patients correlates with lipid peroxidation by-
products [43], while serum MDA is a strong predictor of
prevalent cardiovascular disease in these patients [44].
Besides, the content of AOPP independently predicts
atherosclerotic CV events in non-diabetic pre-dialysis
patients [45]. It is important to note that GST family
members play a dual role in defence mechanisms that
counteract complex biochemical changes present in
uraemic state. Namely, all products of analysed GST
genes possess both glutathione conjugating and antioxi-
dant enzymatic activity [18, 46]. According to the results
presented in this study, the level of protection against both
oxidative and carbonyl stress in uraemic syndrome is in-
ﬂuenced by common GST polymorphisms which deter-
mine the quantity and/or activity of GST protein ‘echelons’
that act upon organic hydroperoxides and accumulated
harmful compounds.
The data concerning genetic predisposition to worse
oxidative phenotype in patients with CRF are limited. Lin
et al. [10] showed that HD patients with the GSTM1-null
genotype are more vulnerable to oxidative DNA damage
and are at greater risk for death compared with those who
possess active GSTM1 genotype. In this study, we ad-
dressed the most relevant classes of oxidative protein and
lipid damage by-products encountered in ESRD, as well
as, TOS and PAB in relation to GSTA1, GSTM1, GSTP1
and GSTT1 genotypes. We found that individual GST
polymorphisms inﬂuence vulnerability to both protein
and lipid oxidation, with GSTM1-null gene variant having
the most pronounced effect. Besides, our results have
shown a strong combined effect of null or low-activity
GSTM1, GSTT1, GSTA1 and GSTP1 genotypes in terms
of susceptibility towards oxidative and carbonyl stress in
patients with ESRD. Our results conﬁrmed similar ﬁnd-
ings presented in patients with benign prostate hyperplasia
in which combined GSTM1-null/GSTT1-null genotype
was associated with increased plasma MDA level [47].
Our study is also consistent with the results of Tang et al.
[48], who showed that coronary artery disease patients
with the GSTM1-null/GSTT1-null genotype have lower
total antioxidant capacity than those with both active gen-
otypes [48]. Besides, this genotype combination was
Fig. 4. TOS and PAB in relation to the GST genotype in ESRD patients. TOS and PAB values increased in patients with null/low-activity GST
genotype (A and B, respectively). *P < 0.05, **P < 0.01.
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Table 4. Biomarkers of oxidative damage in relation to combined GSTA1, GSTM1, GSTP1 and GSTT1 genotypes in ESRD patients (mean ± SD)
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0.029 2.3 ± 0.3
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associated with enhanced DNA damage in many studies
that investigated the role of GST polymorphisms in
relation to cancer risk [49–52]. In the light of the role that
GST enzymes have in detoxiﬁcation and as antioxidant
enzymes, results of this and other studies on association
between null/low-activity GSTM1, GSTT1, GSTP1 and
GSTA1 genotypes and increased oxidant damage of pro-
teins and lipids are biologically plausible. According to
the presence of various GST gene variants in combi-
nation, ESRD patients may be stratiﬁed in terms of level
of oxidative, carbonyl stress and nitrosative stress. Con-
cerning the latter, imbalance in the relative levels of SOD
and GPX, already observed in HD patients [8, 9, 13],
inﬂuences the ratio of nitric oxide: superoxide anion
leading to an increase in peroxynitrite production [53].
Although the association between GST null or low-
activity gene variants and plasma nitrotyrosine level in
ESRD patients was relatively mild, our ﬁndings suggest
that their antioxidant activities at least partially affect the
level of nitrosative damage. Since oxidative stress par-
ameters correlate with CV complications and mortality
[10, 45, 54, 55], it may be speculated that interaction
between the uraemic state and combined GST genotype
would represent at least one of the potential mechanisms
explaining inter-individual differences in terms of CV
outcome in these patients. Certain limitations might be
considered in our study. The case–control design was
used for estimation of associations between GST geno-
types and ESRD development, and therefore, selection
bias might inﬂuence the results. Our control group was
hospital-based, thus the use of population controls may
have been more appropriate. The cross-sectional design
performed for analyses of inﬂuence of GST genotypes on
by-products of oxidative stress did not allow us to investi-
gate the role of GST polymorphisms in the development
of CV complications in ESRD patients. Nevertheless, this
study may offer some essential information that could be
the base for future longitudinal research.
In addition to prognosis, our results may have impli-
cations in new approaches to the antioxidant therapy in
HD patients. The suggested therapeutic interventions
aimed at reducing oxidative stress in HD patients include
biocompatible membranes, administration of antioxidants
and substances indirectly affecting oxidative stress
[11]. Recently, vitamin E-bonded membranes for haemo-
dialysers have been developed, which have a wide spec-
trum of positive effects on antioxidant status in dialysis
patients [56–58]. The results obtained in this study
suggest that the use of dialysers with vitamin E-bonded
membranes would be of most beneﬁt for patients with
combined GST null or low-activity genotypes. Besides,
the GST genotype determination in HD patients could be
a step forward to individualization of antioxidant adminis-
tration. In their recent review, Coumbes and Faset reported
ﬁndings of more than 50 studies in which the effects of
antioxidant therapy were investigated in HD patients.
Only α-tocopherol and N-acetylcysteine treatment consist-
ently decreased oxidative stress. Besides, the authors indi-
cated that future studies need ﬁrst to develop valid
oxidative stress biomarkers before evaluating the efﬁ-
ciency of antioxidant therapy [59]. Since susceptibility to
oxidative damage differs with respect to the GST geno-
type, it seems reasonable to assume that individuals’ GST
‘genetic proﬁle’, in addition to plausible oxidative stress
biomarkers, should be also considered in the optimization
of form, dose and time course of antioxidant treatment.
Based on the results of this investigation, it may be
concluded that the GSTM1-null genotype is associated
with increased risk of ESRD development and enhanced
susceptibility to oxidative stress in dialysis patients. The
presence of GSTT1-null or GSTP1-low-activity (Val/Val
and Ile/Val) genotypes in ESRD patients also signiﬁcantly
inﬂuences the level of oxidative damage by-products, but
not as much as GSTM1-null. However, the effect modiﬁ-
cation with regard to oxidative phenotype in HD patients
is most pronounced if GSTM1- and GSTT1-null as well as
low-activity GSTA1 and GSTP1 genotypes are present in
combination. Taken together, these results suggest a possi-
bility for GST genotype-based stratiﬁcation of ESRD
patients which could improve the attempts towards indivi-
dualization of antioxidant treatment.
Acknowledgements. This study was supported by a Grant 175052 from
Serbian Ministry of Education and Science.
Conﬂict of interest statement. None declared.
References
1. Tarng DC, Huang TP, Wei YH et al. 8-Hydroxy-2-deoxyguanosine of
leukocyte DNA s a marker of oxidative stress in chronic hemodialysis
patients. Am J Kidney Dis 2000; 36: 934–944
2. Tarng DC, Huang TP, Liu TY et al. Effect of vitamin E-bonded mem-
brane on the 8-hydroxy 2′-deoxyguanosine level in leukocyte DNA
of hemodialysis patients. Kidney Int 2000; 58: 790–799
3. Peuchant E, Carbonneau MA, Dubourg L et al. Lipoperoxidation in
plasma and red blood cells of patients undergoing haemodialysis: vi-
tamins A, E and iron status. Free Radic Biol Med 1994; 16: 339–346
4. Maccarrone M, Taccone-Gallucci M, Meloni C et al. Activation of 5-
lipoxygenase and related cell membrane lipoperoxidation in hemodia-
lysis patients. J Am Soc Nephrol 1999; 10: 1991–1996
5. Witko-Sarsat V, Friedlander M, Capeillere-Blandin C et al. Advanced
oxidation protein products as a novel marker of oxidative stress in
uremia. Kidney Int 1996; 49: 1304–1313
6. Miyata T, Ueda Y, Yamada Y et al. Accumulation of carbonyls accel-
erates the formation of pentosidine, an advanced glycation end
product: carbonyl stress in uremia. J Am Soc Nephrol 1998; 9:
2349–2356
7. Locatelli F, Canaud B, Eckardt KU et al. Oxidative stress in end-
stage renal disease: an emerging threat to patient outcome. Nephrol
Dial Transplant 2003; 18: 1272–1280
8. Mimic-Oka J, Simic T, Ekmescic V et al. Erythrocyte glutathione per-
oxidase and superoxide dismutase activities in different stages of
chronic renal failure. Clin Nephrol 1995; 44: 44–48
9. Mimic-Oka J, Simic T, Djukanovic L et al. Alteration in plasma anti-
oxidant capacity in various degrees of chronic renal failure. Clin
Nephrol 1999; 51: 233–241
10. Lin YS, Hung SC, Wei YH et al. GST M1 polymorphism associates
with DNA oxidative damage and mortality among hemodialysis
patients. J Am Soc Nephrol 2009; 20: 405–415
11. Libetta C, Sepe V, Esposito P et al. Oxidative stress and inﬂam-
mation: implications in uremia and hemodialysis. Clin Biochem
2011; 44: 1189–1198
12. Carmagnol F, Sinet PM, Rapin J et al. Glutathione-S-transferase of
human red blood cells; assay, values in normal subjects and in two
pathological circumstances: hyperbilirubinemia and impaired renal
function. Clin Chim Acta 1981; 117: 209–217






/ndt/article-abstract/28/1/202/1827916 by Belgrade U
niversity user on 31 July 2019
13. Mimic-Oka J, Simic T, Djukanovic Lj et al. Glutathione and its
associated enzymes in peripheral blood cells in different stages of
renal insufﬁciency. Amino Acids 1992; 2: 215–224
14. Habig WH, Pabst MJ, Jakoby WB. Glutathione S-transferase—the
ﬁrst enzymatic step in mercapturic acid formation. J Biol Chem
1974; 249: 7130–7139
15. Hayes JD, Strange RC. Glutathione S-transferase polymorphisms
and their biological consequences. Pharmacology 2000; 61:
154–166
16. Board P, Coggan M, Johnston P et al. Genetic heterogeneity of the
human glutathione transferases: a complex of gene families. Phar-
macol Ther 1990; 48: 357–369
17. Carlsten C, Sagoo GS, Frodsham AJ et al. Glutathione S-transferase
M1 (GSTM1) polymorphisms and lung cancer: a literature-based
systematic HuGE review and meta-analysis. Am J Epidemiol 2008;
167: 759–774
18. Simic T, Savic-Radojevic A, Pljesa-Ercegovac M et al. Glutathione
S-transferases in kidney and urinary bladder tumors. Nat Rev Urol
2009; 6: 281–289
19. Miller EA, Pankow JS, Millikan RC et al. Glutathione-S-transfer-
ase genotypes, smoking, and their association with markers of
inﬂammation, hemostasis, and endothelial function: the athero-
sclerosis risk in communities (ARIC) study. Atherosclerosis 2003;
171: 265–272
20. Li R, Boerwinkle E, Olshan AF et al. Glutathione S-transferase gen-
otype as a susceptibility factor in smoking-related coronary heart
disease. Atherosclerosis 2000; 149: 451–462
21. Wiencke JK, Pemble S, Ketterer B et al. Gene deletion of gluta-
thione s-transferase theta: correlation with induced genetic damage
and potential role in endogenous mutagenesis. Cancer Epidemiol
Biomarkers Prev 1995; 4: 253–259
22. Kellen E, Hemelt M, Broberg K et al. Pooled analysis and metaana-
lysis of the glutathione S-transferase P1 ile105val polymorphism
and bladder cancer: a HuGe-GSEC review. Am J Epidemiol 2007;
165: 1221–1230
23. Dusinská M, Ficek A, Horská A et al. Glutathione S-transferase
polymorphisms inﬂuence the level of oxidative DNA damage
and antioxidant protection in humans. Mutat Res 2001; 482:
47–55
24. Zimniak P, Nanduri B, Pilula S et al. Naturally occurring human
glutathione S-transferase GSTP1.1 isoforms with isoleucine and
valine at position 104 differ in enzymatic properties. Eur J Biochem
1994; 244: 893–899
25. Matsui A, Ikeda T, Enomoto K et al. Increased formation of oxi-
dative DNA damage, 8-hydroxy-2′-deoxyguanosine, in human
breast cancer tissue and its relationship to GSTP1 and COMT geno-
types. Cancer Lett 2000; 151: 87–95
26. Garte S, Gaspari L, Alexandrie AK et al. Metabolic gene poly-
morphism frequencies in control populations. Cancer Epidemiol
Biomarkers Prev 2001; 10: 1239–1248
27. Coles FB, Kadlubar FF. Human alpha class glutathione S-trans-
ferases: genetic polymorphism, expression, and susceptibility to
disease. Methods Enzymol 2005; 401: 9–42
28. Ping J, Wang H, Huang M et al. Genetic analysis of glutathione S-
transferase A1 polymorphism in the Chinese population and the
inﬂuence of genotype on enzymatic properties. Toxicol Sci 2006; 89:
438–443
29. Abdel-Rahman SZ, el-Zein RA, Anwar WA et al. A multiplex PCR
procedure for polymorphic analysis of GSTM1 and GSTT1 genes in
population studies. Cancer Lett 1996; 107: 229–233
30. Harries LW, Stubbins MJ, Forman D et al. Identiﬁcation of genetic
polymorphisms at the glutathione S-transferase Pi locus and associ-
ation with susceptibility to bladder, testicular and prostate cancer.
Carcinogenesis 1997; 18: 641–644
31. Jocelyn PC. Spectrophotometric assay of thiols. Methods Enzymol
1987; 143: 44–67
32. Dousset JC, Trouilh M, Foglietti MJ. Plasma malonaldehyde levels
during myocardial infarction. Clin Chim Acta 1983; 129: 319–322
33. Erel O. A new automated colorimetric method for measuring total
oxidant status. Clin Biochem 2005; 38: 1103–1111
34. Alamdari DH, Paletas K, Pegiou T et al. A novel assay for the evalu-
ation of the prooxidant–antioxidant balance, before and after antiox-
idant vitamin administration in type II diabetes patients. Clin
Biochem 2007; 40: 248–254
35. Kao MP, Ang DS, Pall A et al. Oxidative stress in renal dysfunction:
mechanisms, clinical sequelae and therapeutic options. J Hum Hy-
pertens 2010; 24: 1–8
36. Agrawal S, Tripathi G, Khan F et al. Relationship between GSTs
gene polymorphism and susceptibility to end stage renal disease
among North Indians. Ren Fail 2007; 29: 947–953
37. Datta SK, Kumar V, Pathak R et al. Association of glutathione S-
transferase M1 and T1 gene polymorphism with oxidative stress in
diabetic and nondiabetic chronic kidney disease. Ren Fail 2010; 32:
1189–1195
38. Datta SK, Kumar V, Ahmed RS et al. Effect of GSTM1 and GSTT1
double deletions in the development of oxidative stress in diabetic
nephropathy patients. Indian J Biochem Biophys 2010; 47: 100–103
39. Yang Y, Kao MT, Chang CC et al. Glutathione S-transferase T1 del-
etion is a risk factor for developing end-stage renal disease in dia-
betic patients. Int J Mol Med 2004; 14: 855–859
40. Tiwari AK, Prasad P, B KT et al. Oxidative stress pathway genes
and chronic renal insufﬁciency in Asian Indians with Type 2 dia-
betes. J Diabetes Complications 2009; 23: 102–111
41. Klemm A, Voigt C, Friedrich M et al. Determination of erythrocyte
antioxidant capacity in haemodialysis patients using electron para-
magnetic resonance. Nephrol Dial Transplant 2001; 16: 2166–2171
42. Galli F. Protein damage and inﬂammation in uraemia and dialysis
patients. Nephrol Dial Transplant 2007; 22: 20–36
43. Dursun B, Dursun E, Suleymanlar G et al. Carotid artery intima-
media thickness correlates with oxidative stress in chronic haemo-
dialysis patients with accelerated atherosclerosis. Nephrol Dial
Transplant 2008; 23: 1697–1703
44. Boaz M, Matas Z, Biro A et al. Serum malondialdehyde and preva-
lent cardiovascular disease in hemodialysis. Kidney Int 1999; 56:
1078–1083
45. Descamps-Latscha B, Witko-Sarsat V, Nguyen-Khoa T et al. Ad-
vanced oxidation protein products as risk factors for atherosclerotic
cardiovascular events in nondiabetic predialysis patients. Am J
Kidney Dis 2005; 45: 39–47
46. Hayes JD, Strange RC. Potential contribution of glutathione S-trans-
ferase supergene family to resistance to oxidative stress. Free Radic
Res 1995; 22: 193–207
47. Kumar V, Yadav CS, Datta SK et al. Association of GSTM1 and
GSTT1 polymorphism with lipid peroxidation in benign prostate hy-
perplasia and prostate cancer: a pilot study. Dis Markers 2011; 30:
163–169
48. Tang JJ, Wang MW, Jia EZ et al. The common variant in the
GSTM1 and GSTT1 genes is related to markers of oxidative stress
and inﬂammation in patients with coronary artery disease: a case-
only study. Mol Biol Rep 2010; 37: 405–410
49. Kato S, Bowman ED, Harrington AM et al. Human lung carcino-
gen-DNA adduct levels mediated by genetic polymorphisms in vivo.
J Natl Cancer Inst 1995; 87: 902–907
50. Butkiewicz D, Cole KJ, Phillips DH et al. GSTM1, GSTP1,
CYP1A1 and CYP2D6 polymorphisms in lung cancer patients from
an environmentally polluted region of Poland: correlation with lung
DNA adduct levels. Eur J Cancer Prev 1999; 8: 315–323
51. Rojas M, Cascorbi I, Alexandrov K et al. Modulation of benzo[a]
pyrene diolepoxide-DNA adduct levels in human white blood cells
by CYP1A1, GSTM1 and GSTT1 polymorphism. Carcinogenesis
2000; 21: 35–41
52. McCarty KM, Santella RM, Steck SE et al. PAH-DNA adducts,
cigarette smoking, GST polymorphisms and breast cancer risk.
Environ Health Perspect 2009; 117: 552–558
53. Köse FA, Seziş M, Akçiçek F et al. Oxidative and nitrosative stress
markers in patients on hemodialysis and peritoneal dialysis. Blood
Purif 2011; 32: 202–208
54. Bayes B, Pastor C, Bonal J et al. Homocysteine, C-reactive protein,
lipid peroxidation and mortality in haemodialysis patients. Nephrol
Dial Transpl 2003; 18: 106–112






/ndt/article-abstract/28/1/202/1827916 by Belgrade U
niversity user on 31 July 2019
55. Kalantar-Zadeh K, Brennan ML, Hazen SL. Serum myeloperoxidase
and mortality in maintenance hemodialysis patients. Am J Kidney
Dis 2006; 48: 59–68
56. Cruz DN, De Cal M, Garzotto F et al. Effect of vitamin E-coated
dialysis membranes on anemia in patients with chronic kidney
disease: an Italian multicenter study. Int J Artif Organs 2008; 31:
545–552
57. Galli F, Rovidati S, Benedetti S et al. Lipid peroxidation, leu-
kocyte function and apoptosis in hemodialysis patients treated
with vitamin-E modiﬁed ﬁlters. Contrib Nephrol 1999; 127:
156–171
58. Schiecke G, Gwinner W, Radermacher J et al. Long-term effect of
vitamin E-bonded dialysis membrane on mononuclear cell acti-
vation, malondialdehyde generation and endothelial function in
ESRD patients. Contrib Nephrol 1999; 127: 243–250
59. Coombes JS, Fassett RG. Antioxidant therapy in hemodialysis
patients: a systematic review. Kidney Int 2012; 81: 233–246
Received for publication: 6.4.2012; Accepted in revised form: 3.7.2012






/ndt/article-abstract/28/1/202/1827916 by Belgrade U
niversity user on 31 July 2019
